SLU-PP-332 Dosage, half-life & reference guide
Also known as SLU PP 332 · SLUPP332 · SLU-PP332
An experimental "exercise mimetic": a small molecule (not a peptide) from a St. Louis-based academic team that switches on the ERR receptors behind mitochondria and endurance. In mice it lengthened treadmill runs by about 70% and cut fat gain without changing food intake, but it has never been tested in people, and its developers report it lacks oral bioavailability, so what a capsule delivers is unknown.
- Studied range
- 250–1000 mcgstarting dose 250 mcg
- How often
- Daily
- Evidence
- ●
●●Emerging - Route
- Oral capsule
Studied in research — not a recommendation.
How it works.
Synthetic small molecule (not a peptide) that switches on the estrogen-related receptors ERRα, ERRβ and ERRγ, most strongly ERRα. These receptors run the genes behind mitochondria, fat burning and endurance in muscle, so in mice it mimics parts of aerobic training: more oxidative muscle fibers, more energy expenditure and longer treadmill runs. Despite the name, ERRs don't bind estrogen. All of its research is in mice and cells; it has never been given to people in a study, and its own developers report that it lacks oral bioavailability.
Commonly reported: Some users describe cardio feeling easier, without getting as gassed; others notice nothing.
Week by week.
What to expect in the first 8 weeks
- Onset
- Unknown in people
- Peak effect
- Unknown in people
- Duration
- About 8 weeks (community runs)
Day 1–14Animal
Week one: an honest baseline
Commonly reported: some users notice cardio feeling easier within a week or two; many notice nothing. In mice, a week of twice-daily injections was enough to lengthen treadmill runs. How your usual session feels now is the baseline to compare with.
The science
Billon 2023 (ACS Chem Biol): sedentary mice given 50 mg/kg twice daily by injection for 7 days ran about 70% longer and 45% further than untreated mice; after 2 weeks their grip strength rose too, and their muscles shifted toward oxidative type IIa fibers. No study has tested it in people, by mouth or otherwise.
Sources- Billon et al. (2023)
Updated Oct 2026
Day 15–56Animal
How it burns fat
Switching on ERRs makes muscle burn more fat, the way aerobic training does. In obese mice it raised energy expenditure and fat burning and cut fat gain without changing what they ate. No study has measured this in people.
The science
Billon 2024 (JPET): in diet-induced obese and ob/ob mice, SLU-PP-332 raised energy expenditure and fatty-acid oxidation, reduced fat-mass accumulation and improved insulin sensitivity. A 2023 University of Florida news release on the work said obese mice treated twice daily for a month gained 10 times less fat and lost 12% of their body weight while eating the same amount.
Sources- Billon et al. (2024)
- University of Florida News (2023)
Updated Oct 2026
Any dayAnimal
What SLU-PP-332 is built on
Mouse and cell studies since 2023, nearly all from one research group and its collaborators: endurance, obesity, heart failure and kidney aging in mice. It has never been given to people in a study, its developers say it lacks oral bioavailability, and the mouse work used injections. It is an untested research chemical.
The science
Developed as a pan-ERR agonist, most potent at ERRα (Billon 2023). The same group's 2026 paper says SLU-PP-332 lacks oral bioavailability and introduces an orally active successor, SLU-PP-915 (Billon 2026). The mice got 50 mg/kg twice daily by injection; scaled to a 60 kg adult by body surface area (FDA 2005), that is about 240 mg per dose, so community capsules of 250 to 1,000 mcg a day are roughly 500 to 2,000 times lower, by mouth. In muscle cells from inactive women, it raised mitochondrial and antioxidant markers and helped the cells form muscle fibers in a dish (Bonanni 2025). Doping-control labs have mapped its metabolites in human liver preparations (Avliyakulov 2026; Möller 2026).
Sources- Billon et al. (2023)
- Billon et al. (2026)
- FDA dose-conversion guidance (2005)
- Bonanni et al. (2025)
- Avliyakulov et al. (2026)
- Möller et al. (2026)
Updated Oct 2026
With MOTS-c and SS-31Community
Why people pair it with MOTS-c and SS-31
A common community stack aims at mitochondria from three sides: SLU-PP-332 at the ERR receptors, MOTS-c at the AMPK exercise pathway, SS-31 at the inner mitochondrial membrane. With three compounds started together, there is no telling which one did what. Commonly reported: better endurance, credited to the stack as a whole.
The science
Each piece rests on animal or early data for these uses: SLU-PP-332 lengthened runs in mice (Billon 2023), MOTS-c raised physical capacity in mice of all ages (Reynolds 2021), and SS-31 binds cardiolipin in the inner mitochondrial membrane (Szeto 2014). No study has combined them.
Sources- Billon et al. (2023)
- Reynolds et al. (2021)
- Szeto (2014)
Updated Oct 2026
After week 8
Day 57–84Animal
Weeks 8 to 12: where community runs pause
Community runs commonly last about 8 weeks, then pause for about 4; that is convention, not evidence. The longest published treatment ran 8 weeks, in old mice, and no study has followed it in people at all.
The science
Wang 2023 (Am J Pathol): 21-month-old mice treated for 8 weeks showed reversal of age-related kidney changes (albumin in urine, podocyte loss, mitochondrial dysfunction, inflammation). Xu 2024 (Circulation): pan-ERR agonists including SLU-PP-332 improved heart function and survival in mice with pressure-overload heart failure. Neither was designed as a safety study.
Sources- Wang et al. (2023)
- Xu et al. (2024)
Updated Oct 2026
Day 1 is the day you start it.
Mouse and cell studies only; no human studies. Community reports are sparse.
Preliminary research
A typical run.
Run notes
- Cycle
- Community runs commonly last about 8 weeks with about 4 weeks off; no study has tested any schedule in people.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Community use is daily, often split into a morning and an afternoon capsule; no study has tested timing in people. The mice in its studies were dosed twice a day by injection.
- Route
- Oral capsule
- Stacks
- MOTS-c, SS-31
Safety.
Common side effects
- No human safety data
- Unknown long-term effects
Interactions
No interaction data exist. In human liver enzyme preparations it is broken down into many metabolites (doping-control studies), but which enzymes do it, and what that means alongside other medicines, hasn't been studied. Running it with other metabolic compounds (GLP-1 drugs, MOTS-c, 5-Amino-1MQ) is untested. Discuss all your medicines with your clinician.
Safety notes
There is no human safety data: SLU-PP-332 has never been given to people in a published study, so its effects in people, short or long term, are unknown. In mice, 10 days at 50 mg/kg twice daily by injection caused no overt toxicity, with normal blood counts, electrolytes and muscle enzymes. It is sold as a research chemical, so purity, dose and contents aren't regulated, and anti-doping labs are building tests for it: as a compound with no approval for human use, it falls under the World Anti-Doping Agency's ban on non-approved substances (S0), in force at all times. Discuss with your clinician.
Questions people ask.
What is SLU-PP-332?
An experimental "exercise mimetic": a small molecule (not a peptide) from a St. Louis-based academic team that switches on the ERR receptors behind mitochondria and endurance. In mice it lengthened treadmill runs by about 70% and cut fat gain without changing food intake, but it has never been tested in people, and its developers report it lacks oral bioavailability, so what a capsule delivers is unknown.
How is SLU-PP-332 dosed in research?
The research range for SLU-PP-332 is 250–1000 mcg, daily, with a 250 mcg starting dose. Studied in research — not a recommendation.
How long does SLU-PP-332 last?
The half-life of SLU-PP-332 is unknown: never measured in people; in mice, levels in muscle were about three times those in blood 2 hours after an injection.
What do people report on SLU-PP-332?
Commonly reported on SLU-PP-332: some users describe cardio feeling easier, without getting as gassed; others notice nothing.
Is SLU-PP-332 safe?
The research basis for SLU-PP-332 is emerging: primarily preclinical / limited human data. Common side effects in the library: no human safety data and unknown long-term effects.
What does SLU-PP-332 stack with?
Common stacks for SLU-PP-332: MOTS-c and SS-31.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown: never measured in people; in mice, levels in muscle were about three times those in blood 2 hours after an injection
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
PepVault for iPhone
Track SLU-PP-332 in PepVault
Log every dose, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.
Reviewed How we check the library